Increasing Prevalence of Fatty Liver Diseases And Other Liver Disorders Is Anticipated To Drive The Human Liver Model Market During The Forecast Period 2020-2025. Human Liver Models Market size is $163.40M in 2019, growing at a CAGR of 11.4%% during the forecast period 2020-2025.
The Human Liver Model market is growing at a significant rate as the population is increasing rapidly with a cholesterol-rich diet and the fatty liver diseases in people. Fatty liver disease is a condition in which excess fat is stored inside liver cells, making it harder for the liver to function. One cause of fat buildup in the liver is heavy alcohol use, referred to as alcoholic fatty liver disease. This is a common, but preventable disease and is the earliest stage of alcohol-related liver disease. According to research reports, the global prevalence of fatty liver diseases is as high as one billion. In the United States, fatty liver disorders is estimated to be the most common cause of chronic liver disease, affecting between 80 and 100 million individuals.
A liver is a meaty organ that sits on the right side of the belly. Weighing about 3 pounds, the liver is reddish-brown in color and feels rubbery to the touch. Normally you can't feel the liver, because it's protected by the rib cage. The liver executes more than 500 functions such as protein synthesis, xenobiotic metabolism, bile production, and metabolism of carbohydrates, proteins and fats. Development of liver models that can provide a virtual ecosystem that mimics the molecular processes of a liver factory can help understand molecular interactions to network dynamics and whole organ functions. These advanced liver models are mini-organs or organoids that are expected to replicate human liver physiology, anatomy, and functions from molecular layer upward. These functions can be severely degraded by drug induced liver injury, nonalcoholic fatty liver hepatitis B, viral infections, and hepatocellular carcinoma. The ongoing covid-19 pandemic provides opportunity for the research studies to be done in such organoids to understand their reactions to various drug candidates. These liver organoids are less expensive than animal models and also have no ethical concerns since they are developed in laboratory.
North America holds a major share of Human Liver Model market owing to trends of The favorable factors in this region are growing initiatives of government to increase awareness about organoids and also the growing incidence of Non-alcoholic fatty liver disease (NAFLD) in USA, is estimated to boost the market. According to National Center for health statistics 1.8% of adults are diagnosed with liver disease, so there is high demand to study liver related diseases. The increasing average disposable income of the population and rising government investments and funds on healthcare facilities in developed countries such as U.S., Canada and Mexico. The growing awareness regarding health owing to rise in the income of individuals and increase in investments on research that focus on tissue culture-based clinical diagnostics, and availability of skilled professionals in the region are other major factors that are likely to help in the growth of the market in the forecast period. The recent outbreak of the novel coronavirus (COVID-19 pandemic), people in North America countries with underlying liver conditions are more likely to show symptoms of the infection or to have a more severe infection than others, as is the case with flu and other infections. Hence, government is putting focus on the safety and treatment of those patients. Biological engineers and lab experts of Canada are working extensively on a model of the human liver known as the liver chip. This system consists of engineered human liver tissue grown on a specialized scaffold, to test drug toxicity, and to model complicated diseases. There is an Increase in cases related to Liver cancer in the region and, the research currently lacks models that can recapitulate the pathophysiology of the original tumor which has created a need in this regions are set to avail new growth opportunity to Human Liver Model market during 2020-2025.
Talk to one of our sales representative about the full report by providing your details in the link below:
Human Liver Model Market Growth Drivers:
- Increasing R&D funding and venture capital investments for the development of liver models:
Increasing concerns about liver disorders, particularly for NALFD has been a constant source of investment by major companies since the past decade. Various fundings and research grants have motivated to work further for innovation of liver models. The American Association for the Study of Liver Diseases Foundation announced its investment of $4.06 million in research and career development grants awarded to 36 researchers and clinicians also contribute abetting the growth of the market.
- Adoption of Advanced Technology For Health Benefits:
The demand for Human Liver Model is increasing for improvement of health in developing countries owing to treat diseases such as those affecting the liver and the areas surrounding it of elderly and middle-aged patients. Over time, death rates (per 100,000 population) increased from 7.6 to 8.9 for NAFLD and from 5.1 to 7.3 for alcoholic liver disease among the urban population. Increasing awareness about organoids has driven the innovation of human liver models by key market manufacturers. Healthcare delivery in the developing countries is undergoing considerable change, with an increasing focus on quality and value of care, defined as safe, effective, patient-centered, timely, efficient and equitable.
Emulate, Inc., collaborated with Intenze Products, Inc., to develop and use collaboration to use organ-chips to study and for early disease detection and to stimulate human biology for better disease control.
The Major Players in this Market Include
The major companies in the Human Liver Model market include CN Bio Innovations, Corning Incorporated, Emulate, Inc., Hurel Corporation, InSphero, BioIVT, Regenovo, CellLink Lifescience, Pandorum, Organovo Holdings Inc. Organovo Holdings Inc. and others. In 2019, CN Bio Innovations launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic steatohepatitis (NASH) therapeutics.
Over the years, companies have mainly focused on safety and have been investing in developing various technologies to provide treatments for diseases. The advancements in organ printing technologies and the increasing focus on developing alternatives for the animal-based models and accuracy are the major factors set to buoy the Human Liver Model market during 2020-2025.
To request for a quote, provide your details in the below link:
Mr. Venkat Reddy
Email: [email protected]
Contact Sales: +1-970-236-3677
About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.